Drug intelligence / Profile preview

caspase-1 inhibitor (Elgia Therapeutics)

Development stage: Preclinical
Lead developer: Elgia Therapeutics
Modality: Small Molecules

Overview

Elgia Therapeutics' caspase-1 inhibitor is a preclinical small-molecule drug candidate designed to treat chronic inflammatory and fibrotic diseases. It functions by selectively inhibiting caspase-1, a cysteine protease that plays a critical role in the NLRP3 inflammasome pathway. By blocking caspase-1 activity, the drug prevents the proteolytic cleavage and activation of pro-inflammatory cytokines, specifically interleukin-1 beta (IL-1β) and interleukin-18 (IL-18), thereby suppressing downstream inflammatory cascades. The program is currently being evaluated for the treatment of cryopyrin-associated periodic syndrome (CAPS) and inflammatory bowel disease (IBD), including colitis.

Other names: Elgia caspase-1 inhibitor

Targets

CASP1 (Caspase-1)

Beyond the preview

Go deeper on caspase-1 inhibitor (Elgia Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on caspase-1 inhibitor (Elgia Therapeutics).